--- title: GLP-1 Progress Month by Month: Mounjaro, Wegovy, Ozempic url: https://progresslens.app/guides/glp-1-progress-month-by-month/ language: en updated: 2026-11-13 --- # GLP-1 progress month by month By the [ProgressLens team](https://progresslens.app/about/) · Updated November 13, 2026 What month 1, 3 and 6 usually look like on semaglutide or tirzepatide, and what to measure so you can see it. Short answer GLP-1 progress usually starts slower than expected while the dose steps up (about 16–20 weeks), then steadies, and approaches a plateau after about a year. Trial averages: about 15% of bodyweight on semaglutide 2.4 mg and 21% on tirzepatide 15 mg. Track waist, arms and matched photos monthly to see fat loss and catch muscle loss. **On this page** - [The shape of GLP-1 weight loss](#shape) - [What to expect, and what to track, month by month](#months) - [Why monthly photos beat the scale](#photos) - [FAQ](#faq) **Not medical advice.** GLP-1 medications are prescribed and supervised by a clinician. This page explains published trial results and how to track your own body; talk to your prescriber about your dose, protein and training. ## The shape of GLP-1 weight loss Trials start at a low dose and step up every four weeks: semaglutide over about 16 weeks to 2.4 mg, tirzepatide over about 20 weeks to 15 mg. So the first months are often slower than people expect, then loss steadies, and most people approach a plateau after about a year. Trial averages at the end: about 15% of bodyweight on semaglutide 2.4 mg (68 weeks) and about 21% on tirzepatide 15 mg (72 weeks). Individual results vary widely. ### Track every month the same way. Take a check-in, tap AI Analyze and get your Progress Report: body-fat range, what changed, fat or muscle, and whether to cut or bulk. On iPhone, iPad and Android, with no account. Your photos stay on your phone. ## What to expect, and what to track, month by month | Month | What’s typical | What to track | | 1 | Appetite drops; early scale loss is partly water and glycogen; side effects settle. | Starting photos (front, side, back), weight, waist, arms, shoulders. | | 2 | Dose steps up; steadier loss; clothes start to fit differently. | Weekly waist and weight; photos every two weeks. | | 3 | Often the first month you see it in photos side by side. | Compare month 1 and 3 photos; check arms vs waist. | | 4–6 | Steady loss for many people; protein and lifting matter most here. | Strength, arms and shoulders; fat vs muscle check. | | 6–12 | Loss slows toward a plateau. | Waist trend over the scale; decide on maintenance with your clinician. | | 12+ | Maintenance; weight can return if the drug stops. | Monthly photos and waist to catch drift early. | These are patterns, not targets. Compare yourself with your own last month, not with someone else’s Reddit post. ## Why monthly photos beat the scale The scale mixes fat, water and muscle and swings with salt and hormones. Matched photos and a waist measurement show what changed: where you lost it, and whether you look leaner or just smaller. Read [GLP-1 progress photos](https://progresslens.app/guides/glp-1-progress-photos/) for the setup. FAQ ## Frequently asked questions **How much weight do you lose in the first month on Mounjaro or Ozempic?** It varies a lot. The first month is usually on the starting dose, and part of early loss is water. Trials report averages at the end, not per month; compare yourself with your own starting photos and waist. **What does 3 months on tirzepatide look like?** For many people it’s the first time the change is clear side by side in matched photos. Use the same setup as your first photo and compare front and side. **When does GLP-1 weight loss plateau?** In the trials, most people approached a plateau after about a year. **How should I track GLP-1 progress?** Weekly weight and waist, arms and shoulders, and matched photos every two weeks. ProgressLens combines these and flags muscle loss. ## Sources - Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 384:989–1002, with DXA substudy. - Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 387:205–216, with DXA substudy. ## Keep reading [Mounjaro progress trackerWeekly photos and measurements.Read more →](https://progresslens.app/mounjaro-progress-tracker/)[GLP-1: fat or muscle?Drug by drug.Read more →](https://progresslens.app/guides/glp-1-fat-or-muscle/)[GLP-1 weight loss calculatorTrial-based projections.Read more →](https://progresslens.app/tools/glp-1-weight-loss-calculator/) --- ProgressLens is an AI progress photo app for iPhone, iPad and Android that turns your check-in photos and tape measurements into a Progress Report: your body-fat range, what changed, whether you are losing fat or muscle, and whether to cut, lean bulk, recomp or maintain. App Store: https://apps.apple.com/app/progresslens/id6806300575 Google Play: https://play.google.com/store/apps/details?id=app.progresslens